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Abstract
Epistasis is the phenomenon whereby one polymorphism’s effect on a trait depends on other
polymorphisms present in the genome. The extent to which epistasis influences complex traits1
and contributes to their variation2,3 is a fundamental question in evolution and human genetics.
Though often demonstrated in artificial gene manipulation studies in model organisms4,5, and
some examples have been reported in other species6, few examples exist for epistasis amongst
natural polymorphisms in human traits7,8. Its absence from empirical findings may simply be due
to low incidence in the genetic control of complex traits2,3, but an alternative view is that it has
previously been too technically challenging to detect due to statistical and computational issues9.
Here we show that, using advanced computation10 and a gene expression study design, many
instances of epistasis are found between common single nucleotide polymorphisms (SNPs). In a
cohort of 846 individuals with 7339 gene expression levels measured in peripheral blood, we
found 501 significant pairwise interactions between common SNPs influencing the expression of
238 genes (p < 2.91 × 10−16). Replication of these interactions in two independent data sets11,12
showed both concordance of direction of epistatic effects (p = 5.56 ×10−31) and enrichment of
interaction p-values, with 30 being significant at a conservative threshold of p < 0.05/501. Forty-
four of the genetic interactions are located within 2Mb of regions of known physical chromosome
interactions13 (p = 1.8 × 10−10). Epistatic networks of three SNPs or more influence the expression
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levels of 129 genes, whereby one cis-acting SNP is modulated by several trans-acting SNPs. For
example MBNL1 is influenced by an additive effect at rs13069559 which itself is masked by
trans-SNPs on 14 different chromosomes, with nearly identical genotype-phenotype (GP) maps
for each cis-trans interaction. This study presents the first evidence for multiple instances of
segregating common polymorphisms interacting to influence human traits.
In the genetic analysis of complex traits it is usual for SNP effects to be estimated using an
additive model where they are assumed to contribute independently and cumulatively to the
mean of a trait. This framework has been successful in identifying thousands of
associations14. But to date, though its contribution to phenotypic variance is frequently the
subject of debate1–3, there is little empirical exploration of the role that epistasis plays in the
architecture of complex traits in humans7,8. Beyond the prism of human association studies
there is evidence for epistasis, not only at the molecular scale from artificially induced
mutations4 but also at the evolutionary scale in fitness adaptation15 and speciation16.
Methods are now available to overcome the computational problems involved in searching
for epistasis, but its detection still remains problematic due to reduced statistical power. For
example, increased dependence on linkage disequilibrium (LD) between causal SNPs and
observed SNPs17,18, increased model complexity in fitting interaction terms19, and more
extreme significance thresholds to account for increased multiple testing9 all make it more
difficult to detect epistasis in comparison to additive effects. Thus, with small genetic effect
sizes, as is expected in most complex traits of interest14, the power to detect epistasis
diminishes rapidly. There are two simple ways to overcome this problem. One is by using
extremely large sample sizes20; another is by analysing traits that are likely to have large
effect sizes among common variants. Because our focus was to ascertain the extent to which
instances of epistasis arises from natural genetic variation we designed a study around the
latter approach and searched for epistatic genetic effects that influence gene expression
levels. Transcription levels can be measured for thousands of genes and like most complex
diseases, these expression traits are typically heritable21. But unlike complex diseases,
genetic associations with gene expression commonly have very large effect sizes that
explain large proportions of the genetic variance22, making them good candidates to search
for epistasis, should it exist.
In our discovery dataset (Brisbane Systems Genetics Study, BSGS23) of 846 individuals
genotyped at 528,509 SNPs, we used a two stage approach to identify genetic interactions.
First, we exhaustively test every pair of SNPs for pairwise effects against each of 7339
expression traits in peripheral blood (1.03 × 1015 statistical tests, family-wise error rate of
5% corresponding to a significance threshold of p < 2.91 × 10−16, Methods). Second, we
filtered the SNP pairs from stage 1 on LD and genotype class counts, and tested the
remaining pairwise effects for significant interaction terms and used a Bonferroni correction
for multiple testing (estimated type 1 error rate 0.05 ≤ α ≤ 0.14, Methods, Supplementary
Figure S1). Using this design we identified 501 putative genetic interactions influencing the
expression levels of 238 genes (Supplementary Table S1). We used strict quality control
measures to avoid statistical associations being driven by technical artifacts (Methods).
However it remains possible that unexplained technical artifacts may have led to the
significant discovery interactions. Of the 501 discovery interactions, 434 had available data
and passed filtering (Methods) in two independent replication datasets, Fehrmann12 and the
Estonian Genomics Centre University of Tartu (EGCUT)11, in which we saw convincing
evidence for replication. We used the summary statistics from the replication datasets to
perform a meta analysis to obtain an independent p-value for the putative interactions, and
30 were significant after applying a Bonferroni correction for multiple testing (5%
significance threshold p < 0.05/501, Table 1). To quantify the similarity of GP maps
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between the independent datasets (Figure 1) we decomposed the genetic effects of each of
the SNP pairs into orthogonal additive, dominance and epistatic effects (A1, A2, D1, D2, A1
× A2, A1 × D2, D1 × A2, D1 × D2) and tested for concordance of the sign of the most
significant effect (Supplementary Table S3, Methods). Sign concordance between the
discovery and both replication datasets was observed in 22 out of the 30 significantly
replicated interactions (expected value = 7.5 under the null hypothesis of no interactions, p =
3.76 × 10−8).
In addition, using the meta analysis from the replication samples only, we observed that 316
of the remaining 404 discovery SNP pairs had replication interaction p-values more extreme
than the 2.5% confidence interval of the quantile-quantile plot against the null hypothesis of
no interactions where p-values are assumed to be uniformly distributed (p ≪ 1.0×10−16,
Figure 2 and Supplementary Figure S2). Concordance of the direction of the effect of the
largest variance component was also highly significant (p = 5.71 × 10−31, Supplementary
Table S3). The congruence of the epistatic networks in discovery and replication datasets is
shown in Figure 3, demonstrating that these complex genetic patterns are common even
across independent datasets. A further replication was attempted using the Centre for Health
Discovery and Wellbeing (CHDWB) dataset24, but only 20 of the SNP pairs passed filtering
because the sample size was small (n = 139), and likely due to insufficient power we found
no evidence for replication (Supplementary Figure S6). It should be noted that although it is
a necessary step to establish the veracity of the interactions from the discovery set,
replication of epistatic effects in independent samples is difficult in practice due to LD
(Methods).
Though seldom the focus of association studies, SNPs with known main effects are often
tested for A×A genetic interactions9, but our analysis suggests this is unlikely to be the best
strategy for its detection. The majority of our discovery interactions comprised of one SNP
that was significantly associated with the gene expression level in the discovery dataset, and
one SNP that had no previous association22 (439 out of 501, Methods). Only nine
interactions were between SNPs that both had known main effects while 64 were between
SNPs that had no known main effects. Additionally, we observed that the largest epistatic
variance component for the 501 interactions was equally divided amongst A × A, A × D, D ×
A and D × D at the discovery stage (p = 0.22 for departure from expectation). This is not
surprising because these patterns of epistasis used for statistical decomposition are simply
convenient orthogonal parameterisations of a two locus model, and are not intended to
model biological function25.
Of the discovery interactions, 26 were cis-cis acting (within 1Mb of the transcription start
site, mean distance between SNPs was 0.53Mb), 462 were cis-trans-acting, and 13 were
trans-trans-acting. We observed a wide range of significant GP maps (Figure 1) but the
most common pattern of epistasis that we detected involved a trans-SNP masking the effect
of an additive cis-SNP. For example, MBNL1 (involved in RNA modification and
regulation of splicing26) has a cis effect at rs13069559 which in turn is controlled by 13
trans-SNPs and one cis-SNP that each exhibit a masking pattern, such that when the trans-
SNP is homozygous for the masking allele the decreasing allele of the cis-SNP no longer has
an effect (Supplementary Figure S10). Each of these interactions has evidence for
replication in at least one dataset and six are significantly replicated at the Bonferroni level
(Supplementary Figure S3). We see similar epistatic networks involving multiple (eight or
more) trans-acting SNPs for other gene expression levels too, for example TMEM149
(Supplementary Figure S11), NAPRT1 (Supplementary Figure S12), TRAPPC5
(Supplementary Figure S13), and CAST (Supplementary Figure S14). We observed that
from pedigree analysis these five gene expression phenotypes had non-additive variance
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component estimates within the 95th percentile of the 17,994 gene expression phenotypes
that were analysed previously22 (Supplementary Table S2, Methods).
In total the 501 interactions comprised 781 unique SNPs, which we analysed for functional
enrichment (Methods). We tested the SNPs for cell-type specific overlap with
transcriptionally active chromatin regions, tagged by histone-3-lysine-4,tri-methylation
(H3K4me3) chromatin marks, in 34 cell types27 (Supplementary Figure S5). There was
significant enrichment for cis-acting SNPs in haematopoietic cell types only (p < 1 × 10−4
for the three tissues with the strongest enrichment after adjusting for multiple testing).
However trans-acting SNPs did not show any tissue specific enrichment (p > 0.1 for all
tissues). This difference between cis and trans SNPs suggests different roles in epistatic
interactions where tissue specificity is provided by the cis SNPs. There is also enrichment
for cis-SNPs to be localised in regions with regulatory genomic features as measured by
chromatin states28 (Supplementary Figure S4).
We also demonstrate physical organisation of interacting loci within the cell, suggesting a
mechanism by which biological function can lead to epistatic genetic variance. It has been
shown that different chromosomal regions spatially colocalise in the cell through chromatin
interactions13. We cross-referenced our epistatic SNPs with a map of chromosome
interacting regions (n = 96, 139) in K562 blood cell lines29 (Methods) and found that 44
epistatic interactions mapped to within 5Mb (p < 1.8 × 10−10), (Supplementary Figure S15).
Interaction of distant loci may occur through physical proximity in transcriptional factories
that organise across different chromosome regions and can regulate transcription of related
genes30.
Quantifying the importance of epistasis in complex traits in humans remains an open
question. Here we are able to identify 238 gene expression traits with at least one significant
interaction given our experiment-wide threshold, where the minimum estimated variance
explained by the epistatic effects of any interaction was 2.1% of phenotypic variance.
Taking results from our previously published eQTL23 we calculated that 1848 of the 7339
gene expression levels analysed were influenced by additive effects where the estimated
additive variance of a locus was 2.1% or greater. Thus, we can infer that the number of
instances of large additive effects is significantly greater than the number of instances of
large epistatic effects.
In terms of their contribution to complex traits a more important metric might be the
proportion of the variance that the epistatic loci explain2. Taking all additive effects detected
in Powell et al (2012) that have additive variance explaining 2.1% or greater of phenotypic
variance, we calculated that the proportion of total phenotypic variance of all 7339 gene
expression levels explained by additive effects alone was 2.16%. By contrast, the estimated
epistatic variance from the interacting SNPs detected in this study on average explain a total
of 0.22% of phenotypic variance, approximately ten times lower than the estimated additive
variance. There are several caveats to this comparison which we discuss in the Methods.
Overall, we have demonstrated that it is possible to identify and replicate epistasis in
complex traits amongst common human variants, despite the relative contribution of
pairwise epistasis to phenotypic variation being small. The bioinformatic analysis of the
significant epistatic loci suggests that there are a large number of possible mechanisms that
can lead to non-additive genetic variation. Further research into such epistatic effects may
provide a useful framework for understanding molecular mechanisms and complex trait
variation in greater detail. With computational techniques and data now widely available the
search for epistasis in larger datasets for traits of broader interest is warranted.
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Online methods
1 Discovery data
1.1 Data description—The Brisbane Systems Genetics Study (BSGS) comprises 846
individuals of European descent from 274 independent families23. DNA samples from each
individual were genotyped on the Illumina 610-Quad Beadchip by the Scientific Services
Division at deCODE Genetics Iceland. Full details of genotyping procedures are given in
Medland et al.31 Standard quality control (QC) filters were applied and the remaining
528,509 autosomal SNPs were carried forward for further analysis.
Gene expression profiles were generated from peripheral blood collected with PAXgene TM
tubes (QIAGEN, Valencia, CA) using Illumina HT12-v4.0 bead arrays. The Illumina HT-12
v4.0 chip contains 47,323 probes, although some probes are not assigned to RefSeq genes.
We removed any probes that did not match the following criteria: contained a SNP within
the probe sequence with MAF > 0.05 within 1000 genomes data; did not map to a listed
RefSeq gene; were not significantly expressed (based on a detection p-value < 0.05) in at
least 90% of samples. After this stringent QC 7339 probes remained for 2D-eQTL mapping.
These data are accessible through GEO Series accession number GSE53195.
1.2 Normalisation—Gene expression profiles were normalised and adjusted for batch and
polygenic effects. Profiles were first adjusted for raw background expression in each
sample. Expression levels were then adjusted using quantile and log2 transformation to
standardise distributions between samples. Batch and polygenic effects were adjusted using
the linear model
(1)
where μ is the population mean expression levels, c, p, s and a are vectors of chip, chip
position, sex and generation respectively, fitted as fixed effects; and g is a random additive
polygenic effect with a variance covariance matrix
(2)
The parameter  is the variance component for additive background genetic. Here, we are
using family based pedigree information rather than SNP based IBD to account for
relationships between individuals and so ϕjk is the kinship coefficient between individuals j
and k. The residual, e, from equation 1 is assumed to follow a multivariate normal
distribution with a mean of zero. Residuals were normalised by rank transformation and
used as the adjusted phenotype for the pairwise epistasis scan to remove any skewness and
avoid results being driven by outliers. The GenABEL package for R was used to perform the
normalisation32.
2 Exhaustive 2D-eQTL analysis
2.1 Two stage search—We used epiGPU10 software to perform an exhaustive scan for
pairwise interactions, such that each SNP is tested against all other SNPs for statistical
association with the expression values for each of the 7339 probes. This uses the massively
parallel computational architecture of graphical processing units (GPUs) to speed up the
exhaustive search. For each SNP pair there are 9 possible genotype classes. We treat each
genotype class as a fixed effect and fit an 8 d.f. F-test to test the following hypotheses:
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(3)
(4)
where μ is the mean expression level and xij is the pairwise genotype class mean for
genotype i at SNP 1 and genotype j at SNP 2. This type of test does not parameterize for
specific types of epistasis, rather it tests for the joint genetic effects at two loci. This has
been demonstrated to be statistically more efficient when searching for a wide range of
epistatic patterns, although will also include any marginal effects of SNPs which must be
dealt with post-hoc18.
2.1.1 Stage 1: The complete exhaustive scan for 7339 probes comprises 1.03 × 1015 F-tests.
We used permutation analysis to estimate an appropriate significance threshold for the
study. To do this we performed a further 1600 exhaustive 2D scans on permuted phenotypes
to generate a null distribution of the extreme p-values expected to be obtained from this
number of multiple tests given the correlation structure between the SNPs. We took the most
extreme p-value from each of the 1600 scans and set the 5% FWER to be the 95% most
extreme of these p-values, T* = 2.13 × 10−12. The effective number of tests in one 2D scan
being performed is therefore N* = 0.05/T* ≈ 2.33 × 1010. To correct for the testing of
multiple traits we established an experiment wide threshold of Te = 0.05/(N* × 7339) = 2.91
× 10−16. This is likely to be conservative as it assumes independence between probes.
Filtering: We used two approaches to filter SNPs from stage 1 to be tested for significant
interaction effects in stage 2.
Filter 1: After keeping SNP pairs that surpassed the 2.91 × 10−16 threshold in stage 1 only
SNP pairs with at least 5 data points in all 9 genotype classes were kept. We then calculated
the LD between interacting SNPs (amongst unrelated individuals within the discovery
sample and also from 1000 genomes data) and removed any pairs with r2 > 0.1 or D′2 > 0.1
to avoid the inclusion of haplotype effects and to increase the accuracy of genetic variance
decomposition. If multiple SNP pairs were present on the same chromosomes for a
particular expression trait then only the sentinel SNP pair was retained, i.e. if a probe had
multiple SNP pairs that were on chromosomes one and two then only the SNP pair with the
most significant p-value was retained. At this stage 6404 filtered SNP pairs remained.
Filter 2: We also performed a second filtering screen applied to the list of SNP pairs from
stage 1 that was identical to filter 1 but an additional step was included where any SNPs that
had previously been shown to have a significant additive or dominant effect (p <
1.29×10−11) were removed22, creating a second set of 4751 unique filtered SNP pairs.
2.1.2 Stage 2: To ensure that interacting SNPs were driven by epistasis and not marginal
effects we performed a nested ANOVA on each pair in the filtered set to test if the
interaction terms were significant. We did this by contrasting the full genetic model (8 d.f.)
against the reduced marginal effects model which included the additive and dominance
terms at both SNPs (4 d.f.). Thus, a 4 d.f. F-test was performed on the residual genetic
variation, representing the contribution of epistatic variance. Significance of epistasis was
determined using a Bonferroni threshold of 0.05/(6404+4751) = 4.48×10−6. This resulted in
406 and 95 SNP pairs with significant interaction terms from filters 1 and 2, respectively.
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2.2 Type 1 error rate—Using a Bonferroni correction of 0.05 in the second stage of the
two stage discovery scan implies a type 1 error rate of α = 0.05. However, this could be
underestimated because the number tests performed in the second stage depends on the
number of tests in the first stage, and this depends on statistical power and model choice.
We performed simulations to estimate the type 1 error rate of this study design.
We assumed a null model where there was one true additive effect and 7 other terms with no
effect. To simulate a test statistic we simulated 8 z-scores,  and z2..8 ~ N(0,
1). Thus  (representing the 8 d.f. test) and  (representing
the 4 d.f. test where the null hypothesis of no epistasis is true). For a particular value of NCP
we simulated 100,000 z values, and calculated the pfull-value for the zfull test statistic. The
nint test statistics with pfull < 2.31 × 10−16 were kept for the second stage, where the type 1
error rate of stage 2 was calculated as the proportion of pint < 0.05/nint. The power at stage 1
was calculated as nint/100, 000. This procedure was performed for a range of NCP
parameters that represented power ranging from ~ 0 to ~ 1.
2.3 Population stratification—We ruled out population stratification as a possible cause
of inflated test statistics. To test for cryptic relatedness driving the interaction terms we
tested for increased LD among the SNPs33. We calculated the mean of the off-diagonal
elements of the correlation matrix of all unique SNPs from the 501 interactions (731 SNPs)
using only unrelated individuals, . This is not significantly different from the null
hypothesis of zero (sampling error = 1/nunrelated = 0.0039).
2.4 Probe mapping—To avoid possibility that epistatic signals might arise due to
expression probes hybridising in multiple locations we verified that probe sequences for
genes with significant interactions mapped to only a single location. As an initial
verification we performed a BLAST search of the full probe sequence against 1000 genomes
phase 1 version 3 human genome reference and ensured that only one genomic location
aligned significantly (p < 0.05). As a second step, to mitigate the possibility of weak
hybridisation elsewhere in the genome we divided the probe sequence into three sections (1–
25bp, 13–37bp, 26–50bp) and performed a BLAST search of these probe sequence
fragments. No probe sequemces or probe sequence fragments mapped to positions other than
the single expected genomic target (p < 0.05).
3 Replication
3.1 Data description—We attempted replication of the 501 significant interactions from
the discovery set using three independent cohorts; Fehrmann, EGCUT, and CHDWB. It was
required that LD r2 < 0.1 and D′2 < 0.1 between interacting SNPs (as measured in the
replication sample directly), and all nine genotype classes had at least 5 individuals present
in order to proceed with statistical testing for replication in both datasets. We also excluded
any putative SNPs that had discordant allele frequencies in any of the datasets. Details of the
cohorts are as follows.
Fehrmann: n = 1240 The Fehrmann dataset12 consists of peripheral blood samples of 1240
unrelated individuals from the United Kingdom and the Netherlands. Some of these
individuals are patients, while others are healthy controls. Individuals were genotyped using
the Illumina HumanHap300, Illumina Human-Hap370CNV, and Illumina 610 Quad
platforms. RNA levels were quantified using the Illumina HT-12 V3.0 platform. These data
are accessible through GEO Series accession numbers GSE20332 and GSE20142.
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EGCUT: n = 891 The Estonian Genome Center of the University of Tartu (EGCUT) study11
consists of peripheral blood samples of 891 unrelated individuals from Estonia. They were
genotyped using the Illumina HumanHap370CNV platform. RNA levels were quantified
using the Illumina HT-12 V3.0 platform. These data are accessible through GEO Series
accession number GSE48348.
CDHWB: n = 139 The Center for Health Discovery and Well Being (CD-HWB) Study24 is
a population based cohort consisting of 139 individuals of European descent collected in
Atlanta USA. Gene expression profiles were generated with Illumina HT-12 V3.0 arrays
from peripheral blood collected from Tempus tubes that preserve RNA. Whole genome
genotypes were measured using Illumina OmniQuad arrays. Due to the small sample size,
most SNP pairs did not pass filtering in this dataset (20 SNP pairs remained) and so we have
excluded it from the rest of the analysis.
3.2 Meta Analysis—The 4 d.f. interaction p-values for each independent replication
dataset were calculated using the same statistical test as was performed in the discovery
dataset. We then took the interaction p-values from EGCUT and Fehrmann and calculated a
joint p-value using Fisher’s method of combining p-values for a meta analysis as
. As in the discovery analysis, all gene expression levels were
normalised using rank transformation to avoid skew or outliers in the distribution34.
3.3 Concordance of direction of effects—We used four methods to calculate the
concordance of the direction of effects between the discovery and replication datasets.
Test 1: Is the most significant epistatic effect in the discovery set in the same direction as the
same epistatic effect in the replication sets? We decomposed the genetic variance into 8
orthogonal effects, four of which are epistatic (A×A, A × D, D × A, D × D). The sign of the
epistatic effect that had the largest variance in the discovery was recorded, and then was
compared to the same epistatic effect in the two replication datasets (regardless of whether
or not the same epistatic effect was the largest in the replication datasets). The probability of
the sign being the same in one dataset is 1/2. The probability of the sign being the same in
two is 1/4.
Test 2: Is the most significant epistatic effect in the discovery the same as the largest
epistatic effect in the replication set with the sign being concordant. As in Test 1, but this
time we required that the largest effect was the same in the discovery and the replication,
and that they had the same sign (e.g. if the largest effect in the discovery is A×A, with a
positive effect, then concordance is achieved if the same is true in the replication). The
probability of one replication dataset being concordant by chance is 1/8, and concordance in
both is 1/64.
Test 3: Do the epistatic effects that are significant at nominal p < 0.05 in the discovery have
the same direction of effect as in the replication? Here we count all the epistatic variance
components in the discovery that have p < 0.05 (1133 amongst the 434 discovery SNP pairs,
i.e. each SNP pair has at least 1 and at most 4 significant epistatic variance components).
Then we compare the direction of the effect in the replication dataset. The probability of the
sign being the same in one dataset for any one significant effect is 1/2. The probability of the
sign being the same in two is 1/4.
Test 4: If we count how many of the 4 epistatic effects are concordant between the
discovery and replication data for each interaction then is this significant from what we
expect by chance? There can be either 0, 1, 2, 3 or 4 concordant signs at each interaction,
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each with expectation of p = 1/16, 4/16, 6/16, 4/16, 1/16 under the null, respectively.
Observed counts are multinomially distributed, and we tested if the observed proportions
were statistically different from the expected proportions using an approximation of the
multinomial test35.
The probability of observing the number of concordant signs in tests 1–3 is calculated using
a binomial test. All variance decompositions were calculated using the NOIA method36.
4 Effects of LD on detection and replication
The power to detect genetic effects, when the observed markers are in LD with the causal
variants, is proportional to rx. For additive effects x = 2, but for non-additive effects x is
larger, i.e. x = 4 for dominance or A × A, x = 6 for A × D or D × A, and x = 8 for D × D.
Many biologically realistic GP maps may be comprised of all 8 variance components18.
This is important for both detection and for replication of epistasis. For detection, if the
epistatic effect includes the D × D term then if the two causal variants are tagged by
observed markers that are each in LD r = 0.9, then if the true variance is Vt then the
observed variance Vo at the markers will be 0.98Vt = 0.43Vt. Therefore, it is important to
consider the sampling variation of r̂x in a sample given some true population value of r.
4.1 Simulation 1—For some values of fixed population parameters, p1 (minor allele
frequency at observed marker), q1 (minor allele frequency at causal variant), and r (LD
between marker and causal variant), the expected haplotype frequencies are
(5)
(6)
(7)
(8)
where p2 = 1 − p1 and q2 = 1 − q1. For a range of population parameters we randomly
sampled 2n haplotypes where the expected haplotype frequencies were h11, h12, h21, h22.
From the sample haplotype frequencies we then calculated sample estimates of r̂ where
(9)
For each value of combination of the parameters p1, q1, r, n 1000 simulations were
performed and the sampling mean and sampling standard deviation of r̂, r̂2, r̂4, r̂6, r̂8 were
recorded. It was observed that sampling variance increases for increasing x in r̂x.
4.2 Simulation 2—We assume that the discovery SNP pairs are ascertained (from a very
large number of tests) have high r̂ between observed SNPs and causal variants because
otherwise power of detection would be low. We can hypothesis that the distribution of r̂ in
this ascertained sample will be a mixture of r that is high and r that is lower but with
ascertained higher values from sampling. Therefore, we would expect those with truly high r
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to have a higher replication rate in independent datasets, and those with ascertained high r̂ to
have lower replication because resampling is unlikely to result in the same extreme
ascertainment. To obtain empirical estimates of r̂ in discovery and replication datasets we
conducted the following simulation.
1. Using 1000 genomes data (phase 1, version 3, 379 European samples) we selected
the 528,509 “markers” used in the original discovery analysis, plus 100,000
randomly chosen “causal variants” (CVs) with minor allele frequence > 0.05.
2. The 379 individuals were split into discovery (190) and replication (189) sets.
3. For each CV the marker with the maximum  from the marker panel was recorded
in the discovery set. This marker was known as the “discovery marker” (DM).
4. The  for each CV/DM pair was then calculated in the replication set where the
discovery LD was ascertained to be high, such that .
We observed that there was an average decrease in  relative to , and that this decrease
was larger with increasing x. We observed that  whereas
. The average drop in in replication r̂8 was3 times higher than the drop
in r̂2.
4.3 Interpretation—Simulation 1 shows that sampling variance of rx increases as x
increases. Detection of epistatis is highly dependent upon high r̂. Amongst the discovery
SNPs there will be a mixture of interactions where observed SNPs are either in true high LD
with causal variants, or will have highly inflated sample r̂x compared to the population rx.
Simulation 2 shows that as x gets larger, the average decrease in r̂x between discovery and
replication becomes larger, likely to be a result of ascertained high r̂ in the discovery and
increased sampling variance with increasing x in the replication. These results demonstrate
that if all else is equal, the impact of sampling variance of r alone will reduce the replication
rate of epistatic effects compared to additive effects.
5 Additive and non-additive variance estimation
5.1 Fixed effects—To compare the relative contribution to the phenotypic variance of
gene expression levels between additive and epistatic effects we are constrained by the
problem that non-additive variance components for a phenotype cannot be calculated
directly. Here, we only have SNP pairs that exceed a threshold of p < 2.91 × 10−16 = Te. A
strong conclusion cannot be made about the genome-wide variance contribution, but we can
compare the variance explained by SNP effects at this threshold for additive scans and
epistatic scans.
In Powell et al 201223 an expression quantitative trait locus (eQTL) study was performed
searching for additive effects in the same BSGS dataset as was used for the discovery here.
Using the threshold Te for the additive eQTL study, 453 of the 7339 probes analysed here
had at least one significant additive effect. Assuming that the phenotypic variance for each
of the probes is normalised to 1, the total phenotypic variance of all 7339 explained by the
significant additive effects was 1.73%.
Following the same procedure, at the threshold Te there were 238 gene expression probes
with at least one significant pairwise epistatic interaction out of the 7339 tested. In total the
proportion of the phenotypic variance explained by the epistatic effects at these SNP pairs
was 0.25%.
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5.2 Limitations of this type of comparison—Though it is useful to compare the
relative variances of epistatic and additive effects, it must be stressed that our results here
are approximations that are very limited by the study design. We estimate that additive
effects explain approximately 10 times more variance than epistatic effects, but this could be
an overestimate or an underestimate due to a number of different caveats. Firstly, the ratio of
additive to epistatic variance may differ at different minimum variance thresholds, and our
estimate is determined by the threshold used. Secondly, the power of a 1 d.f. test exceeds
that of an 8 d.f. test. Thirdly, the non-additive variance at causal variants is expected to be
underestimated by observed SNPs in comparison to estimates for additive variance. And
forthly, the extent of winner’s curse in estimation of effect sizes may differ between the two
studies.
5.3 Pedigree estimates—The gene expression levels for MBNL1, TMEM149, NAPRT1,
TRAPPC5 and CAST are influenced by large cis-trans epistatic networks (eight interactions
or more). Though it is not possible to orthogonally estimate the non-additive genetic
variance for non-clonal populations, an approximation of a component of non-additive
variance can be estimated using pedigree information. The BSGS data is comprised of some
related individuals and standard quantitative genetic analysis was used to calculate the
additive and dominance variance components for each gene expression phenotype in Powell
et al 201322. The dominance effect is likely to capture additive × additive genetic variance
plus some fraction of other epistatic variance components. We found that the
aforementioned genes had dominance variance component estimates within the top 5% of all
17,994 gene expression probes that were analysed in Powell et al 2013.
6 Functional enrichment analysis
6.1 Tissue specific transcriptionally active regions—We employed a recently
published method (http://www.broadinstitute.org/mpg/epigwas/)27 that tests for cell-type-
specific enrichment of active chromatin, measured through H3K4me3 chromatin marks37 in
regions surrounding the 731 SNPs that comprise the 501 discovery interactions. The exact
method used to perform this analysis has been described previously38. Briefly, we tested the
hypothesis that the 731 SNPs were more likely to be in transcriptionally active regions (as
measured by chromatin marks) than a random set of SNPs selected from the same SNP chip.
This hypothesis was tested for 34 cell types across four broad tissue types (haematopoietic,
gastrointenstinal, musculoskeletal and endocrine, and brain).
6.2 Chromosome interactions—It has been shown13 that different regions on different
chromosomes or within chromosomes spatially colocalise within the cell. We shall refer to
the colocalisation of two chromosome regions as a chromosome interaction. A map of
pairwise chromosome interactions for K562 blood cell lines was recently produced29, and
we hypothesised that part of the underlying biological mechanism behind some of the 501
epistatic interactions may arise from chromosome interactions. We found that 44 of the
putative epistatic interactions were amongst SNPs that were within 5Mb of known
chromosome interactions. This means that SNP A was no more than 2.5Mb from the focal
point of the chromosome interaction on chromosome A, and SNP B was no more than
2.5Mb from the focal point on chromosome B.
We performed simulations to test how extreme the observation of 44 epistatic interactions
overlapping with chromosome interactions is compared to chance. Chromosome interactions
fall within functional genomic regions13,29, and the SNPs in our epistatic interactions are
enriched for functional genomic regions. Therefore, we designed the simulations to ensure
that the null distribution was of chromosome interactions between SNPs enriched for
functional genomic regions but with no known epistatic interactions. To do this we used the
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731 SNPs that form the 501 putative epistatic interactions and randomly shuffled them to
create new sets of 501 pairs, disallowing any SNP combinations that were in the original set.
Therefore, each new random set was enriched for functional regions but had no genetic
interactions. We scanned the map of chromosome interactions for overlaps with the new sets
and then repeated the random shuffling process. We performed 1,000 such permutations to
generate a null distribution of chromosome interaction overlaps.
We repeated this process, searching for overlaps within 1Mb, 250kb, and 10kb.
6.3 SNP colocalisation with genomic features—We tested for enrichment of
genomic features for the 687 IndexSNPs that comprise the 434 epistatic interactions with
data present in discovery and replication datasets. For each of the 687 IndexSNPs we
calculated LD with all regional SNPs within a radius of 0.5Mb and kept all regional SNPs
with LD r2 > 0.8. We then cross-referenced the remaining regional SNPs with the annotated
chromatin structure reference28) querying whether the regional SNPs fell in Predicted
promoter region including TSS (TSS), Predicted promoter flanking region (PF), Predicted
enhancer (E), Predicted weak enhancer or open chromatin cis regulatory element (WE),
CTCF enriched element (CTCF), Predicted transcribed region (T), or Predicted Repressed or
Low Activity region (R) positions. Therefore a particular IndexSNP might cover multiple
genomic features through LD.
We then performed the whole querying process for each of the 528,509 SNPs present in the
SNP chip used in the scan, and used the results from this second analysis to establish a null
distribution for the expected proportion of SNPs for each genomic feature. We calculated p-
values for enrichment of each of the seven genomic features independently, and for cis- and
trans-SNPs separately, using a binomial test. For each genomic feature we used the expected
proportion of SNPs as the expected probability of “success” (p). Here, a success is defined
as an IndexSNP residing in a region that includes the genomic feature. The observed number
of successes for each IndexSNP (k) out of the total count of IndexSNPs (n) was then
modelled as .
6.4 Transcription factor enrichment—To test for enrichment of transcription factor
binding sites (TFBS) we followed a procedure similar to that described in Section 6.3. For
each of the 687 IndexSNPs we extracted regional SNPs as previously described. We then
used the PWMEnrich package in Bioconductor (http://www.bioconductor.org/packages/
2.12/bioc/html/PWMEnrich.html) to identify which TFBSs each of the regional SNPs for
one IndexSNP falls in (within a radius of 250bp). Thus, the number of occurrences of a
particular TFBS was counted for each IndexSNP. We used the “Threshold-free affinity”
method for identifying TFBSs39.
We constructed a null distribution of expected TFBS occurrences based on the same null
hypothesis as described in Section 6.3 - the probability of an IndexSNP covering a particular
TFBS is identical to any of the 528,509 SNPs in the discovery SNP chip. To do this, we
performed the same procedure for each SNP in the discovery SNP chip as was performed for
each IndexSNP to obtain an expected probability of covering a particular TFBS. We then
tested the IndexSNPs for enrichment of each TFBS independently, and for cis- and trans-
SNPs separately. p-values were obtained using Z-scores, calculated by using a normal
approximation to the sum of binomial random variables representing motif hits along the
sequence40.
Hemani et al. Page 12
Nature. Author manuscript; available in PMC 2014 October 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
6.5 Defining previously identified SNP associations—The discovery dataset
(BSGS) had previously been analysed for additive and dominant marginal effects for all
gene expression levels22,23. To define SNPs that had been previously detected to have
effects for a particular gene expression level we used a significance threshold accounting for
multiple testing across SNPs and expression probes, Tm = 0.05/(528509 × 7339) = 1.29 ×
10−11. From this, we found that only nine of the 501 discovery interactions had known main
effects, 64 were between SNPs that had no known marginal effects, and 439 were between a
SNP with a known marginal effect and a SNP with no known marginal effect.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Replication of GP maps in two independent populations
The GP maps for each epistatic interaction that is significant at the Bonferroni level in both
replication datasets are shown. Each GP map consists of nine tiles where each tile represents
the expression level for that two-locus genotype class. Phenotypes are for gene transcript
levels (dark coloured tiles = high expression, light coloured tiles = low expression).
Columns of GP maps are for each independent dataset. Rows of GP maps are for each of 30
significantly replicated interactions at the Bonferroni level, corresponding to the rows in
Table 1. There is a clear trend of the GP maps replicating across all three datasets.
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Figure 2. Q-Q plots of interaction p-values from replication datasets
The top panel shows all 434 discovery SNPs that were tested for interactions. Observed p-
values (y-axis, −log10 scale) are plotted against the expected p-values (x-axis, −log10 scale).
The multiple testing correction threshold for significance following Bonferroni correction is
denoted by a dotted line. The bottom panel shows the same data as the top panel but
excluding the 30 interactions that were significant at the Bonferroni level in the replication
datasets. The shaded grey area represents the 5% confidence interval for the expected
distribution of p-values. Dark blue points represent p-values that exceed the confidence
interval, light blue are within the confidence interval.
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Figure 3. Discovery and replication of epistatic networks
All 434 putative genetic interactions (edges) with data common to discovery and replication
sets is shown, where black nodes represent SNPs and red nodes represent traits (gene
expression probes). Three hundred and forty-five interactions had p-values exceeding the
2.5% confidence interval following meta analysis of the replication data The remaining 89
interactions that did not replicate are depicted in grey. It is evident that a large proportion of
the complex networks identified in the discovery set also exist in independent populations.
An interactive version of this graph can be found here: http://kn3in.github.io/detecting_epi/
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